EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles

Li Chen, Wuyu Mao iD, Changyu Ren, Jinqi Li, Jifa Zhang iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.3c01802 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Li Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Joint Research Institution of Altitude Health and Institute of Respiratory Health and National Clinical Research Center for …. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-pim-1, Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 148 Literaturangaben. Gefördert von: Health Commission of Sichuan Province, Science and Technology Department of Sichuan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proviral integration sitea for Moloney-murine leukemia virus (PIM) kinases are a family of highly conserved serine/tyrosine kinases consisting of three members, PIM-1, PIM-2, and PIM-3. These kinases regulate a wide range of substrates through phosphorylation and affect key cellular processes such as transcription, translation, proliferation, apoptosis, and energy metabolism. Several PIM inhibitors are currently undergoing clinical trials, such as a phase I clinical trial of Uzanserti (5) for the treatment of relapsed diffuse large B-cell lymphoma that has been completed. The current focus encompasses the structural and biological characterization of PIM, ongoing research progress on small-molecule inhibitors undergoing clinical trials, and evaluation analysis of persisting challenges in this field. Additionally, the design and discovery of small-molecule inhibitors targeting PIM in recent years have been explored, with a particular emphasis on medicinal chemistry, aiming to provide valuable insights for the future development of PIM inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-pim-1NeoplasmsMiceAnimalsHumansProtein Serine-Threonine KinasesPhosphorylationProtein Kinase Inhibitors

Substanzen

Proto-Oncogene Proteins c-pim-1Protein Serine-Threonine KinasesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Neurology, Joint Research Institution of Altitude Health and Institute of Respiratory Health and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, S…
  • Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan, China.
  • Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, Sichuan, China.
  • Department of Pharmacy, Chengdu Fifth People's Hospital, Chengdu 611130, Sichuan, China.

ORCID-Profile: Wuyu Mao, Jifa Zhang

Förderung

  • Health Commission of Sichuan Province
  • Science and Technology Department of Sichuan Province
  • National Natural Science Foundation of China

Zitieren

APA

Chen, L., Mao, W., Ren, C., Li, J., & Zhang, J. (2024). Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01802

Vancouver

Chen L, Mao W, Ren C, Li J, Zhang J. Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01802

BibTeX
@article{Chen2024,
  author = {Chen, Li and Mao, Wuyu and Ren, Changyu and Li, Jinqi and Zhang, Jifa},
  title = {Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.3c01802}
}
Kostenlos starten →